OriGene Technologies, Inc., a Rockville, MD-based genome wide product company for research and diagnostic applications, completed a $21.3m Series C financing.
The round was led by Qiming Venture Partners and Kleiner Perkins Caufield Byers China, with participation from previous investor IDG-Accel.
The company intends to use the proceeds to advance its growth strategy and operations.
Led by Wei-Wu He , Ph.D., Chairman and Chief Executive Officer, OriGene Technologies develops, manufactures, and sells genome wide research and diagnostic products worldwide. The company has developed an array of ultra-specific monoclonal antibodies called UltraMAB™ which are validated by its proprietary high density microarray technology for a wide variety of applications.